

Diabetes ECHO 2025 *presents:* Review of SGLT-2 Inhibitors

Thursday, May 8, 2025
12 noon - 1:00 PM, CST



Dr. Shaveta Gupta
Tulane University

OBJECTIVES:

1. Review current available agents and cardiorenal risk reduction in high risk individuals
2. Understanding the mechanisms for therapeutic promise and risks
3. Contraindications/Precautions/Adverse Effects

Please scan the QR code or click [here](#) to visit our web page.

AMA Designation Statement

Project ECHO® designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Designation Statement

This activity will provide pharmacists up to 1.0 contact hour. UAN JA4008231-9999-25-027-L01-P has been assigned to this Knowledge based program for Pharmacists. CE credit information, based on verification of live attendance and completion of the program evaluation, will be provided to NABP within 60 days after the activity completion.

ANCC Designation Statement

Project ECHO® designates this live activity for a maximum of 1.0 ANCC contact hour. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation.

Disclosure Statement


Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is in a position to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.




MEET THE HUB TEAM



Christine Castille,
FNP-C, BC-ADM, CDE



Anthony Decuir, Jr.,
DPM



Satish Gadi
MD, FACC, FSCAI



Raven Jackson
PharmD, MBA



Dragana Lovre
MD



Vy Anh Mai
MD, MS